Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18412485 | ENTEROVIRUS MULTI-ANTIGEN EPITOPE FUSION PROTEIN, GENE, VACCINE, AND PREPARATION METHOD THEREOF | January 2024 | June 2024 | Allow | 5 | 0 | 0 | No | No |
| 18388792 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | November 2023 | February 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18463276 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | September 2023 | December 2023 | Allow | 3 | 1 | 0 | No | No |
| 18202596 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | May 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18314052 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | May 2023 | December 2023 | Allow | 7 | 0 | 0 | No | No |
| 18169440 | STEROID ACID-BASED IMMUNOGEN ENHANCERS | February 2023 | April 2024 | Allow | 14 | 1 | 0 | No | No |
| 18081782 | ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 18065083 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18080101 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18080075 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065089 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18080090 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | June 2023 | Allow | 6 | 1 | 0 | No | No |
| 18065109 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065106 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065069 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065095 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065111 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065076 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18065100 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18080275 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18064168 | ANTIGEN PRESENTING SCAFFOLDS FOR IMMUNE-CELL MANIPULATION | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18063823 | Compositions and Methods for Antigen Targeting to CD180 | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 17990848 | METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIES | November 2022 | January 2024 | Allow | 14 | 1 | 0 | No | No |
| 17966954 | VIRUS AND ANTIGEN PURIFICATION AND CONJUGATION | October 2022 | March 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17961005 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | October 2022 | June 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17948008 | HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES | September 2022 | April 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17813445 | METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINS | July 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17867466 | ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF | July 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17811250 | ROTAVIRUS VACCINES | July 2022 | June 2023 | Allow | 11 | 0 | 0 | No | No |
| 17854891 | PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY CONSTRUCTS | June 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17854205 | METHODS OF USING LOW DOSE VOLUME B-CELL EPITOPE COMPOSITIONS FOR INDUCING AN ANTIBODY IMMUNE RESPONSE IN HUMAN SUBJECTS | June 2022 | March 2024 | Allow | 20 | 2 | 0 | No | No |
| 17854462 | METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEIN | June 2022 | February 2024 | Allow | 19 | 2 | 0 | No | No |
| 17849392 | RSV IMMUNIZATION REGIMEN | June 2022 | September 2023 | Allow | 15 | 1 | 1 | No | No |
| 17847629 | MUMPS VIRUS AS A POTENTIAL ONCOLYTIC AGENT | June 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17845583 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | June 2022 | November 2022 | Allow | 5 | 1 | 0 | No | No |
| 17831024 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | June 2022 | November 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17749973 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | May 2022 | August 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17742221 | ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES | May 2022 | June 2023 | Allow | 13 | 1 | 0 | No | No |
| 17738548 | STEROID ACID-BASED IMMUNOGEN ENHANCERS | May 2022 | January 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17661379 | HUMANIZED ANTI-CLAUDIN-1 ANTIBODIES AND USES THEREOF | April 2022 | May 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17685717 | COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF | March 2022 | June 2023 | Allow | 15 | 1 | 1 | No | No |
| 17578094 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | January 2022 | April 2022 | Allow | 3 | 0 | 0 | No | No |
| 17558852 | INFLUENZA VIRUS MUTANTS AND USES THEREFOR | December 2021 | January 2024 | Allow | 25 | 2 | 0 | No | No |
| 17534659 | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES | November 2021 | October 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17511762 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | October 2021 | January 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17507113 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | October 2021 | May 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17504002 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | October 2021 | February 2023 | Allow | 16 | 0 | 0 | No | No |
| 17405748 | HUMANIZED INFLUENZA MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF | August 2021 | April 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17405884 | MODIFIED HEPATITIS C VIRUS E2 GLYCOPROTEINS AND METHODS OF USE THEREOF | August 2021 | December 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17385465 | IMMUNOGENETIC RESTRICTION ON ELICITATION OF ANTIBODIES | July 2021 | July 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17375797 | INFLUENZA VACCINES | July 2021 | April 2023 | Allow | 21 | 1 | 0 | No | No |
| 17422835 | RECOMBINANT VARICELLA-ZOSTER VIRUS (VZV) VACCINE | July 2021 | March 2024 | Allow | 32 | 0 | 0 | No | No |
| 17369091 | INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS | July 2021 | July 2023 | Allow | 24 | 1 | 0 | No | No |
| 17352845 | MUTATIONS THAT CONFER GENETIC STABILITY TO ADDITIONAL GENES IN INFLUENZA VIRUSES | June 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17349558 | GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICS | June 2021 | March 2023 | Allow | 21 | 2 | 1 | Yes | No |
| 17324494 | HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOF | May 2021 | March 2023 | Allow | 22 | 1 | 0 | No | No |
| 17323082 | Methods and Compositions for Inducing an Immune Response Against Hepatitis B Virus (HBV) | May 2021 | October 2022 | Allow | 17 | 0 | 0 | No | No |
| 17322604 | USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALS | May 2021 | February 2024 | Allow | 33 | 0 | 0 | No | No |
| 17320046 | REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES | May 2021 | May 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17316834 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | May 2021 | May 2023 | Allow | 24 | 1 | 0 | No | No |
| 17234145 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | April 2021 | July 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17231782 | DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES | April 2021 | April 2022 | Allow | 12 | 0 | 0 | No | No |
| 17200745 | METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES | March 2021 | December 2022 | Allow | 21 | 1 | 0 | No | No |
| 17186941 | VACCINES FORMED BY VIRUS AND ANTIGEN CONJUGATION | February 2021 | January 2023 | Allow | 23 | 1 | 0 | No | No |
| 17176777 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | February 2021 | July 2021 | Allow | 5 | 2 | 0 | Yes | No |
| 17161997 | Immunogenic Compositions to Treat and Prevent Microbial Infections | January 2021 | September 2023 | Allow | 32 | 2 | 1 | No | No |
| 17157335 | METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIES | January 2021 | July 2022 | Allow | 18 | 1 | 0 | No | No |
| 17147137 | METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINS | January 2021 | April 2022 | Allow | 15 | 0 | 0 | No | No |
| 17131104 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | December 2020 | May 2022 | Allow | 17 | 1 | 0 | No | No |
| 17251869 | ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTION | December 2020 | April 2024 | Allow | 40 | 1 | 0 | No | No |
| 16972367 | METHOD FOR EFFICIENTLY INDUCING ANTIBODY, ANTIBODY AND DETECTION SYSTEM FOR HEPATITIS VIRUS | December 2020 | August 2022 | Allow | 21 | 1 | 1 | No | No |
| 15734670 | MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 18 | December 2020 | May 2023 | Allow | 29 | 1 | 1 | No | No |
| 17109851 | COMPOSITIONS AND RELATED METHODS FOR CONTROLLING VECTOR-BORNE DISEASES | December 2020 | February 2024 | Allow | 38 | 1 | 1 | No | No |
| 15734148 | HEPATITIS B VACCINE TRANSNASAL ADMINISTRATION SYSTEM | December 2020 | April 2024 | Allow | 40 | 1 | 0 | No | No |
| 17059934 | HEPATITIS B ANTIBODIES | November 2020 | December 2023 | Allow | 36 | 0 | 0 | No | No |
| 17100857 | METHOD FOR ROBUST CONTROL OF GENE EXPRESSION | November 2020 | June 2023 | Allow | 31 | 1 | 0 | No | No |
| 17057230 | ECHO-7 ONCOLYTIC VIRUS FOR USE IN THE TREARMENT OF UVEAL MELANOMA | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17057489 | USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENT | November 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 16952864 | CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS | November 2020 | May 2022 | Allow | 18 | 1 | 0 | No | No |
| 17055817 | TREATMENT AND PREVENTION OF HOUSE DUST MITE ALLERGIES | November 2020 | May 2023 | Allow | 30 | 2 | 1 | No | No |
| 17052591 | USE FOR PREVENTING AND TREATING MYELOID-DERIVED SUPPRESSOR CELL-RELATED DISEASES | November 2020 | June 2024 | Allow | 43 | 1 | 0 | No | No |
| 17081124 | Humanized Anti-Claudin-1 Antibodies and Uses Thereof | October 2020 | January 2022 | Allow | 15 | 0 | 0 | No | No |
| 17071976 | SUBJECT ANTI-HCV ANTIBODY DETECTION ASSAYS EMPLOYING NS3 CAPTURE PEPTIDES | October 2020 | January 2022 | Allow | 16 | 0 | 0 | No | No |
| 17067929 | Use of CD24 Proteins for Treating Leptin-Deficient Conditions | October 2020 | July 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17046487 | AAV VECTORS ENCODING CLARIN-1 OR GJB2 AND USES THEREOF | October 2020 | March 2024 | Allow | 41 | 1 | 0 | No | No |
| 17045393 | METHOD FOR DETECTING NUCLEIC ACID BASED ON PROKARYOTIC ARGONAUTE PROTEIN AND APPLICATION THEREOF | October 2020 | June 2024 | Allow | 44 | 1 | 0 | No | No |
| 17043847 | NOVEL SALMONELLA TYPHIMURIUM BACTERIOPHAGE STP-2 AND USE THEREOF FOR INHIBITING PROLIFERATION OF SALMONELLA TYPHIMURIUM | September 2020 | March 2024 | Allow | 42 | 1 | 0 | No | No |
| 17041784 | METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING HEMAGGLUTININ | September 2020 | September 2022 | Allow | 24 | 1 | 1 | No | No |
| 17016246 | TREATMENT AND PREVENTION OF GENITAL WARTS | September 2020 | January 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17007095 | MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | August 2020 | December 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16992188 | ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | August 2020 | September 2022 | Allow | 25 | 0 | 0 | No | No |
| 16939266 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | July 2020 | January 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 16919943 | VACCINES FORMED BY VIRUS AND ANTIGEN CONJUGATION | July 2020 | January 2023 | Allow | 31 | 1 | 1 | No | No |
| 16957931 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS | June 2020 | February 2023 | Allow | 32 | 3 | 0 | No | No |
| 16895958 | BINDING MOLECULES TARGETING PATHOGENS | June 2020 | August 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16884505 | HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES | May 2020 | May 2022 | Allow | 24 | 2 | 0 | No | No |
| 16864087 | ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF | April 2020 | November 2021 | Allow | 19 | 0 | 0 | No | No |
| 16759898 | ANTI-CAR COMPOSITIONS AND METHODS | April 2020 | June 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16759670 | IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF | April 2020 | September 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16647705 | MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOF | March 2020 | December 2023 | Allow | 45 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOESEN, AGNIESZKA.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BOESEN, AGNIESZKA works in Art Unit 1648 and has examined 700 patent applications in our dataset. With an allowance rate of 52.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner BOESEN, AGNIESZKA's allowance rate of 52.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOESEN, AGNIESZKA receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BOESEN, AGNIESZKA is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +33.2% benefit to allowance rate for applications examined by BOESEN, AGNIESZKA. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 37.9% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 75.7% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 67.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 77% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.